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The complement system is an important immune mechanism mediating both recognition and elimination of foreign bodies.
The lectin pathway is one pathway of three by which the complement system is activated. The characteristic protease of this
pathway is Mannan-binding lectin (MBL)-associated serine protease 2 (MASP2), which cleaves complement proteins C2 and C4.
We present a novel and alternative role of MASP2 in the innate immune system. We have shown that MASP2 is capable of
promoting fibrinogen turnover by cleavage of prothrombin, generating thrombin. By using a truncated active form of MASP2
as well as full-length MASP2 in complex with MBL, we have shown that the thrombin generated is active and can cleave both
factor XIII and fibrinogen, forming cross-linked fibrin. To explore the biological significance of these findings we showed that
fibrin was covalently bound on a bacterial surface to which MBL/MASP2 complexes were bound. These findings suggest that,
as has been proposed for invertebrates, limited clotting may contribute to the innate immune response.
Citation: Krarup A, Wallis R, Presanis JS, Ga ´l P, Sim RB (2007) Simultaneous Activation of Complement and Coagulation by MBL-Associated Serine
Protease 2. PLoS ONE 2(7): e623. doi:10.1371/journal.pone.0000623
INTRODUCTION
The immune system is composed of many recognition and effector
mechanisms the primary role of which is to eliminate invading
pathogens, altered host cells and macromolecules. The comple-
ment system is one such system, and it is composed mainly of
plasma proteins of which several circulate as serine protease
zymogens. These, when activated, catalyse downstream events of
the complement system resulting in an inflammatory response,
direct lysis and opsonization of microorganisms. The complement
system can become activated by any of three pathways: the
classical pathway relies on C1q binding, which enables the
protease zymogen C1r to auto-activate and subsequently activate
another protease zymogen C1s. The active C1s then cleaves C4
and C2 to trigger the downstream reaction [1]. The other two
activation pathways are initiated by spontaneous hydrolysis of C3
(alternative pathway) or upon binding of mannan-binding lectin
(MBL) or ficolins to sugars or N-acetylated groups on the surface
of microorganisms (lectin pathway) [2]. Neither MBL nor ficolins
possess enzyme activity themselves but rely on the MBL-associated
serine proteases (MASPs)1, 2 and 3, with which they circulate in
complexes [3]. When MBL, L-ficolin or H-ficolin bind to
a bacterial surface, the MASPs, which are homologues of C1r
and C1s, become activated. Of the three MASPs only MASP2
is capable of activating complement by cleavage of C4 and C2.
[4].
The coagulation system is another protein cascade of which
most components circulate in plasma. The main role of the
coagulation system is not neutralization of invading pathogens but
to maintain the integrity of the circulatory system upon injury.
The coagulation system can be activated by two pathways, the
intrinsic and the extrinsic, of which both lead to the formation of
the prothrombinase complex on phospholipid membranes. The
prothrombinase complex is made up of factor Va and factor Xa
and generates active thrombin by factor Xa-mediated double
cleavage of prothrombin [5]. The generation of thrombin is
regarded as the critical step in the coagulation cascade since
thrombin mediates the functions that leads to the formation of
blood clots by cleavage of fibrinogen and factor XIII and
activation of platelets [6].
The complement and the coagulation systems have many
similarities since both cascades utilize as catalysts multi-domain
serine proteases with similar domain structure. The similarity of
the two systems on the structural level can be demonstrated with
phylogenetic analysis in which the proteases of the classical and the
lectin pathways become grouped together with coagulation
enzymes [7]. Both cascade systems are tightly regulated whereby
the active enzymes have a short half-life but this is overcome by
end-product amplification that is characteristic for protein
cascades. The coagulation system serine proteases are regulated
by serpins and secondarily by a2-Macroglobulin [8]. The C1r,
C1s, MASP1 and MASP2 proteases are also regulated by a serpin
(C1-inhibitor) but MASP1 and MASP2 regulation is more similar
to that of coagulation proteases, since both also are inhibited by
anti-thrombin III and a2-Macroglobulin [9,10].
The similarities generally suggest that the proteases of the
two protein cascades have originated from the same ancestral
proteases. Here we have investigated a possible link on the
functional level between the two systems since we have demon-
strated that MASP2 is capable of activating prothrombin in
a similar manner to factor Xa. Furthermore the MASP2-
generated thrombin is able to cleave synthetic tripeptide substrates
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factor XIII. This activity was identifiable both in fluid-phase by
using a truncated rMASP2 construct (trMASP2) and a full-length
rMASP2 bound to MBL. These findings indicate a possible
physiological role for fibrinogen in the innate immune system of
vertebrates, perhaps analogous to the suggested roles of co-
agulation in defense of invertebrates against infection [11].
RESULTS
When prothrombin activation by factor Xa is analyzed by SDS-
PAGE a complex fragmentation pattern is observed, since both
factor Xa and the generated thrombin can each cleave pro-
thrombin twice [5]. A schematic overview of the possible
prothrombin fragments generated by factor Xa and thrombin is
shown in fig 1A. In fig 1B we show SDS-PAGE analysis of the
fragmentation of prothrombin when incubated with factor Xa or
trMASP2. Identification of the bands was carried out by N-
terminal sequencing and by comparing the observed molecular
masses determined by their migration in SDS-PAGE gels to the
calculated masses based on the primary sequence. Factor Xa and
trMASP2 both generate the same cleavage fragments although in
different quantities. Fragment 1.2 and prethrombin 2 is seen in
both gel tracks, indicating that factor Xa and trMASP2 cleave at
the fXa1 site (Arg
273-Thr
274). This was confirmed by N-terminal
sequencing of the prethrombin 2 fragment formed by trMASP2
(fig 1C). The second factor Xa cleavage (fXa2, Arg
322-Ile
323) is not
visible with either factor Xa or trMASP2 (fig 1B) perhaps because
the heavy chain coruns with fragment 1.2, and the light chain is
too small to be observed on the gel. However the fXa2 cleavage,
which generates active thrombin, must occur with both factor Xa
and trMASP2, as products of both the thrombin-mediated
cleavages *1 and *2 are seen in fig 1B. These products are (*1)
prethrombin 1 (fragment 1 has migrated off the gel) and (*2) the
31.5 and 33.8 kDa fragments. The N-termini of all the fragments
visible on figure 1B were confirmed (fig 1C) except for the
33.8 kDa fragment in the trMASP2 lane (quantity too low). We
were unable to detect all the products but this is due to lack of
sensitivity of our detection system rather than them not being
generated. Activation of prothrombin is a very rare proteolytic
specificity. Apart from tryptase, the BRENDA enzyme database
Figure 1. Prothrombin fragmentation. A) Prothrombin fragments generated during activation by factor Xa and cleavage by thrombin as would be
observed on SDS-PAGE under reducing conditions (based on ref (5)). The arrows indicate the cleavage sites for factor Xa (fXa1 Arg273-Thr274 and
fXa2 Arg322-Ile323) and thrombin (*1 Arg155-Ser156 and *2 Arg286-Thr287). The molecular mass of the fragments shown was calculated based on
the primary sequence (Swiss-Prot entry P08709). B) The observed cleavage pattern of prothrombin incubated with factor Xa (FXa) (lane 1) or trMASP2
(lane 2) for 4 h at 37uC and analyzed by reducing SDS-PAGE and Coomassie Blue staining. The bands were identified by N-terminal sequencing
together with theoretical and observed size. The 33.8 kDa fragment migrates faster than the 31.5 kDa fragment due to differences in the number of
N-linked glycosylations. C) The sites of cleavage by factor Xa and trMASP2 are identical as confirmed by N-terminal sequencing as described in the
text.
doi:10.1371/journal.pone.0000623.g001
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protease which does this. In contrast to trMASP2, truncated
rMASP1 (trMASP1) does not cleave prothrombin (not shown).
To investigate to what extent thrombin generation proceeds we
incubated factor Xa and trMASP2 with prothrombin, then
measured the thrombin activity using a tripeptide substrate
VPR-AMC which is selective for thrombin. The results are
displayed in figure 2. Factor Xa alone, trMASP2 alone or
prothrombin alone turn over the substrate to a negligible extent.
However when factor Xa or trMASP2 are incubated with
prothrombin, there is increased substrate turnover, consistent
with generation of thrombin. Thrombin generation was further
confirmed by studying fibrinogen turnover (see below). In the
experiment shown in fig 2 prothrombin concentration is 100 mg/
ml (approximately physiological). trMASP2 (100 ng) generates at
each point about 20% as much thrombin activity as 25 ng factor
Xa. Therefore, we assume that 25 ng trMASP2 would generate
only 4–5% as much thrombin as 25 ng factor Xa. In fig 2, the
curves are non-linear, as more thrombin is being generated with
time. This leads to upward curvature. At later times substrate
depletion and the instability of all 3 proteases leads to lower rates
of substrate turnover. The observed reaction measures only
production of active thrombin by 2 cleavages of prothrombin by
factor Xa or trMASP2. However the competing reaction, 2
cleavages by thrombin to produce inactive products, is not
measured directly but contributes to substrate depletion.
Factor Xa alone, however is not the major physiological
activator of prothrombin. This is carried out by the factor Xa-
factor Va prothrombinase complex which is the major activator
during coagulation.
Results in fig 2 were obtained with a truncated version of the
MASP2 enzyme produced in E.coli, which lacks the CUB1-EGF-
CUB2 domains which interact with MBL. We wanted to
investigate if full-length MASP2 in complex with MBL also is
capable of activating prothrombin when bound to a surface. To do
this we used rat rMBL-A [12] and rat rMASP2K [13] using
mannan as an activating surface. On mannan-coated microtiter
plate wells MBL/MASP2K complexes were bound and incubated
with prothrombin and VPR-AMC or fibrinogen. The results from
these experiments can be seen in figure 3A and B, respectively.
Figure 3A shows that only MBL/MASP2K complexes bound in
the presence of Ca
2+ ions and incubated with prothrombin
generate active thrombin. All of the negative controls, i.e. MBL/
MASP2K incubated with mannan in the presence of EDTA
(where the complexes will not form and MASP2K is not activated),
the controls with no MASP2K or with no prothrombin show no
ability to cleave the substrate above background level (fig 3A
columns 2, 3 and 4).
Figure 3B shows how the turbidity of a fibrinogen solution
changes due to fibrin polymerization. A series of dilutions of
MBL/MASP2K were bound in mannan-coated wells and sub-
sequently incubated with prothrombin and fibrinogen. As can be
observed the higher concentrations of rMBL/rMASP2K lead to
polymerization and increase of light scatter at 405 nm showing the
ongoing polymerization. The reaction has not reached its endpoint
since the turbidity only is 35–40% of the value seen when active
thrombin was directly added to the fibrinogen. Figure 3C shows
SDS-PAGE analysis of fibrinogen following incubation in the
mannan-coated wells with rMBL/MASP2K. Fibrinogen is
a hexamer composed of 2 a,2b and 2 c chains. Upon activation
by thrombin the a and b chains are cleaved and the fibrinopep-
tides A and B are released. At the same time thrombin cleaves
factor XIII generating factor XIIIa which is a transglutaminase
capable of stabilizing fibrin clots by covalent linking of two c-
chains or multiple a-chains forming the c2 and the an oligomer
[14]. It was not necessary to add any factor XIII to the
experiments since it is found in all fibrinogen preparations as
a contaminant and its transglutaminase activity, i.e. the generation
of the c2 and multiple an oligomer, was used as a marker for early
stage clot formation. Cleavage of the a and b chains and formation
of c2 and an clearly occurs in lane 1 which represents the MBL/
MASP2K complexes bound in the presence of Ca
2+ ions and
incubated with prothrombin and fibrinogen. In the control lanes
where MBL/MASP2K complexes were incubated in the presence
of EDTA, or in the absence of MASP2K or prothrombin (lanes 2,
3 and 4) no fibrinogen cleavage or cross-linking can be observed.
These experiments confirm that the MBL/MASP2K can generate
functional thrombin, detected by activation of factor XIII and
fibrinogen, which are two of the major protein substrates of
thrombin.
The specificity of the thrombin activation by MASP2 was
examined in 2 ways. Firstly homologues of MASP2 namely C1r
and C1s (and trMASP1, see above) were tested for their capacity
to generate thrombin. Secondly trMASP2 was incubated with
other protease proenzymes to see if active proteases were
generated. We incubated prothrombin alone or with activated
C1s or a mixture of activated C1r and C1s. Factor Xa was the
positive control. Prothrombin activation was observed by analyz-
ing cleavage patterns on reducing SDS-PAGE. As can be seen in
figure 4 C1r and C1s do not cleave prothrombin. This shows that
the ability of MASP2 to activate prothrombin is relatively specific.
Additional experiments performed with other plasma protease
proenzymes, prekallikrein and plasminogen showed that neither
trMASP1 nor trMASP2 significantly cleaves prekallikrein during
1 h or 16 h incubation. Neither protease cleaves plasminogen to
form the heavy and light chains of plasmin within 16 h at 37uC, as
assessed by SDS-PAGE analysis (not shown). Incubation does not
lead to the generation of the active proteases within 2 h at 37uC
when investigated by using specific plasmin and kallikrein
tripeptide substrates (not shown). These results confirm that the
Figure 2. Thrombin activity generated by factor Xa and trMASP2
measured by cleavage of VPR-AMC. Samples (100 ml) contained 10 mg
prothrombin (PT)+25 ng factor Xa (fXa), 25 ng factor Xa alone, 10 mg
prothrombin+100 ng trMASP2, 100 ng trMASP2 alone or 10 mg pro-
thrombin alone. As can be observed the cleavage of the substrate by
factor Xa, trMASP2 and prothrombin is negligible, but incubation of
prothrombin with factor Xa or trMASP2 generates activity. The figure
shows the development of the relative fluorescence at different time
points. A typical result from 3 experiments is shown.
doi:10.1371/journal.pone.0000623.g002
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and is unique for C4 and C2 cleaving enzymes.
Since MASP2 circulates in complex with MBL and the ficolins
and these have to bind to the surface of targets (eg bacteria) before
MASP2 becomes activated, it was of interest to see if binding of
the MBL/MASP2K complexes would result in fibrin deposition
on the surface upon which the complex is bound. To investigate
this two experiments were designed. In the first (fig 5A) we
r
Figure 3. VPR-AMC cleavage (A), fibrin aggregation (B) and
fibrinogen cleavage and cross-linking (C) by thrombin generated
by mannan-bound MBL/MASP2K. In fig 3A, thrombin generation is
shown by cleavage of VPR-AMC. Column 1 shows the VPR-AMC turn-
over when MBL/MASP2K was incubated with mannan in the presence
of Ca
2+ ions, followed by addition of prothrombin. Column 2 is the
control for column 1 where MBL/MASP2K complexes were bound in the
presence of EDTA. Column 3 is a further control with no rMASP2 added,
and Column 4 is the same as column 1, but without prothrombin. The
figure shows the cleavage of VPR-AMC by thrombin (as relative
fluorescence) after 4h at 37uC. Fig 3B shows the MBL/MASP2K dose-
dependent fibrin polymerization in a microtiter well after incubation
with prothrombin and fibrinogen for 3.5 hours. The X-axis shows a 2-
fold dilution series of the MBL/MASP2K complexes starting at 200 ng/
well. The background was defined as the activity from a sample in
which MBL/MASP2K complexes were prevented from binding by the
presence of EDTA and subtracted. Fig 3C shows generation of
fibrinogen c chain dimer and a chain oligomers. Sample numbers
correspond to those in fig 3A. Only in lane 1 have the c chain dimer as
well as a chain oligomers been formed. This arises from fibrinogen
activation followed by factor XIIIa mediated cross-linking. This occurs
only in the presence of activated MBL/MASP2K complexes bound to
mannan, and in the presence of prothrombin. A typical result from 3
experiments is shown.
doi:10.1371/journal.pone.0000623.g003
Figure 4. Reducing SDS-PAGE of prothrombin incubated at 37uC for
4 hours alone or with activated C1s, activated C1r,C1s mixture or
factor Xa. Neither C1s alone or C1r, C1s mixtures are capable of
cleaving prothrombin. Factor Xa is included as a positive control.
doi:10.1371/journal.pone.0000623.g004
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coated plate and measured the deposition of
125I-fibrinogen in the
wells after prothrombin activation. The column labeled positive is
the sample in which MBL/MASP2K complexes were bound in
the presence of Ca
2+ ions and subsequently incubated with
125I-
fibrinogen and prothrombin. The remaining two controls are
either without MASP2K or without prothrombin. As can be
observed the prothrombin activation by MASP2K leads to
125I-
fibrin deposition in the wells showing that target surfaces indeed
do get fibrin deposited. In this type of experiment no
125I-fibrin
binding was found if the plate was coated with only mannan.
However if a mixture of mannan and a protein (fibrinogen, b-
casein or thiolester-cleaved a2M) was used,
125I-fibrin was bound.
This is consistent with the need for glutamine or lysine side chains
on the surface to which factor XIIIa can mediate covalent linkage.
To investigate the deposition of fibrin further we derivatized beads
with a non-encapsulated S. aureus strain (Wood), previously shown
to be capable of binding MBL, to assess if fibrin deposition also
happens on microorganisms [15]. MBL/MASP2K complexes
were then bound to these beads, and prothrombin and
125I-
fibrinogen added. After incubation the beads were washed and the
associated radioactivity was measured. Column 2 and 5 on
figure 5B show that only the beads incubated with MBL/
MASP2K complexes get
125I-fibrin deposited on the surface. In
the presence of iodoacetamide (IAM) however, the deposited fibrin
could be removed by incubation with urea (Column 5, open bar)
while this was not possible in the sample without IAM (Column 2,
open bar). This is because IAM is an inhibitor of factor XIIIa,
which is responsible for covalent cross-linking of fibrin strands.
Therefore the fibrin deposited in the sample with IAM is not
covalently cross-linked and gets disrupted upon urea treatment. In
the sample without IAM the factor XIIIa does covalently cross-link
the fibrin, presumably to bacterial surface proteins strengthening
the fibrin/bacterium complex. The prolonged incubation time was
necessary since the fibrinogen concentration used was approxi-
mately 100-fold lower than under physiological conditions to
prevent the formation of a solid clot.
DISCUSSION
The role of fibrinogen in the human immune defense is not well
explored but in some lower invertebrates like the horseshoe crab
Tachypleus tridentatus a fibrinogen functional analogue, coagulogen,
is regarded as a contributor to host defense. In T. tridentatus the
clotting factors are found in hemocyte granules of which the
contents are released on detection of LPS or peptidoglycan. The
secretion leads, by two pathways, depending on the substance
encountered, to the cleavage and activation of the proclotting
enzyme generating the clotting enzyme. The clotting enzyme
cleaves coagulogen, which afterwards can polymerize forming an
insoluble gel aggregating the invading microorganisms [11].
There are many functional similarities between the horseshoe
crab coagulation system and the mammalian since both are
regulated by serpin type protease inhibitors, rely on cascade events
to mount a powerful response and are mainly activated at the site
of tissue damage [11,16]. Additionally the proteins involved in the
activation of clotting in T. tridentatus such as factor B (the protease
which activates the proclotting enzyme if LPS is present), the
proclotting enzyme and coagulogen appear to be functional
Figure 5. Fibrin deposition on MBL target surface. Fig 5A shows
125I-fibrin deposition on a mannan/fibrinogen coated surface to which rMBL/
rMASP2K complexes are bound. The background (a control in which rMBL/rMASP2K complexes were prevented from binding to the surface due to
the presence of EDTA) has been subtracted from the remaining samples. The figure shows that deposition above background level only occurs if
rMASP2K is present and if the incubation with fibrinogen is in the presence of prothrombin. Incubation was for 4h at 37uC. Fig 5B
125I-fibrin
deposition on S. aureus-derivatized beads. S. aureus-derivatized beads were incubated at 4uC with rMBL/rMASP2 complexes and subsequently with
prothrombin and
125I-fibrinogen for 7 h at 37uC. The figure shows that fibrin gets deposited on the beads upon activation of prothrombin by rMBL/
rMASP2 complexes (columns 2 and 5, closed bars). The fibrin bound to the surface also gets covalently cross-linked to the bacteria since it was not
removed by washing the beads with urea (column 2, open bar). If the deposition was done in the presence of iodoacetamide (IAM), which inhibits
factor XIIIa, the radioactivity associated with the beads was reduced to background level upon urea extraction (column 5, open bar). In the controls in
which no rMASP2 was added or in the presence of protease inhibitors (C1 inhibitor or Pefabloc SC) no deposition on the beads could be observed.
Each sample was tested twice and the error bars represent one standard deviation from the mean.
doi:10.1371/journal.pone.0000623.g005
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despite differences on the structural level. What sets the
invertebrate and mammalian cascades apart is the knowledge of
their roles as immune defense mechanisms. As mentioned above
T. tridentatus use clotting to aggregate pathogens as well as
maintaining hemostasis. In mammals the clotting system is mainly
believed to be involved in maintaining hemostasis but recent
reports also indicate that fibrin(ogen) and fibrinogen activation
products might also play an important part in mediating clearance
of pathogens. Upon activation of fibrinogen the fibrinopeptides A
and B are released and these are chemotactic factors capable of
recruiting neutrophils, macrophages and fibroblasts to the site of
fibrinogen turnover [17–20]. Also fibrin(ogen) deposition in itself
has been investigated for direct effects on pathogen neutralization.
The role of fibrinogen has been investigated in in vivo studies using
fibrinogen deficient mice or mice with modified fibrinogen, where
binding of complement receptor 3 to fibrin(ogen) is prevented.
These studies showed that fibrin(ogen) restrains the growth of
Listeria monocytogenes in infected hepatic tissue and aids the bacterial
clearance of S. aureus from the peritoneal cavity [21,22].
Fibrin(ogen) has also been shown to increase adherence of
phagocytes when biomaterials have been used as model for
foreign bodies [23]. These observations indicate that fibrin(ogen)
plays a role in the neutralization of invading pathogens since it
mediates both migration and adhesion of phagocytes and in some
cases, dependent on the pathogen, is capable of limiting growth as
well as causing them to aggregate.
What we have reported here is a link between the complement
system and the coagulation system. As the results show MASP2 is
capable of generating thrombin via prothrombin. This activation
is specific, in that MASP2 homologues do not activate pro-
thrombin, and MASP2 does not activate other protease proen-
zymes. The activation occurs at physiological levels of pro-
thrombin. The thrombin activation potential is quite low (about 4–
5% the rate observed with factor Xa) and presumably much lower
than would be observed for the prothrombinase complex. Since
the prothrombinase complex mainly is generated on phospholipid
membranes at the site of tissue damage a rapid and local thrombin
generation is required to prevent loss of blood. In the case of
MASP2 it will activate prothrombin near any surface where MBL
or the ficolins can bind. Such surfaces do not have to be localized
in one area but might be transported in the bloodstream round the
body. If MASP2 was as efficient as the prothrombinase complex
the activation of MASP2 could lead to thrombosis and therefore
do more harm than good. Formation of a large clot around the
MBL/ficolin-binding particle might well inhibit subsequent
clearance by phagocytes as well. Instead MASP2 has a low
activation potential but this ensures that only a limited amount of
thrombin is generated and due to the surplus of inhibitors that are
found in plasma it will only be active for a short time. This has two
effects: firstly not much fibrin will be generated (probably not
enough for forming a solid clot) and secondly the active thrombin
will only remain active close to the site of activation since it most
likely will be inhibited before it can diffuse far from the activation
site. The limited, localized thrombin activity generated increases
the chance of fibrin being deposited on the surface to which
MASP2 is bound. This will result in the release of fibrinopeptides
A and B and the deposition of fibrin that attracts phagocytes and
serve as adhesion points for the immune system cells.
This activity might be a remnant activity of MASP2 from some
ancestralprotease.When C1swas testedwe saw no abilityto activate
prothrombin, despite MASP2 and C1s being considered to be of
common origin and being close homologues. It has previously been
shown that MASP1 has thrombin-like activity, and activates factor
XIII and cleaves fibrinogen directly [24]. When MBL or ficolins,
with associated MASP1, 2 and3 bind totargets (eg bacteria) MASP2
can subsequently activate the complement system through cleavage
of C4 and C2. Both MASP1 and MASP2 may contribute to
localized fibrinogen activation. The role of MASP3 remains
unknown. We are currently studying the relative roles of MASP1
and MASP2 in fibrinogen and factor XIII activation.
Recently another study showed, like this one, that complement
and coagulation might be more closely linked than previously
believed. It was observed that C3 knock-out mice were capable of
generating C5a. This activity was inhibitable by hirudin, a specific
thrombin inhibitor, suggesting that this C5a generation was
dependent on thrombin [25]. As our studies show, MBL/ficolin
MASP2 complexes could contribute to the formation of thrombin
required for the mechanism postulated in ref [25]. However
incubation of C5 with thrombin does not produce significant
cleavage of C5, when analyzed on SDS-PAGE (Krarup, un-
published observation) therefore one or more intermediate
proteases might be required. Both our study and ref [25] suggest
that the coagulation system and the complement system may be
interconnected in several ways, reflecting their common origin and
that they might be able to supplement each other to some extent in
the case of deficiencies.
MATERIALS AND METHODS
Biochemical methods
SDS-PAGE was done by the Laemmli system [26] or the
Invitrogen NuPAGEH system (Invitrogen, Paisley, UK). Reducing
sample buffer (0.2M Tris-HCl, 8M urea, 2% SDS, 2mM EDTA,
pH 8.0) was prepared as described by Fairbanks et al (1971) [27].
Radio-iodination of fibrinogen was carried out using iodogen as
catalyst [28] with 50 mg fibrinogen (Enzyme Research Laborato-
ries Ltd, Swansea, UK) in 500 ml of 1.5 mM KH2PO4, 8.1 mM
Na2HPO4, 140 mM NaCl, 2.7 mM KCl, 0.5 mM EDTA, pH 7.4
(PBS/EDTA) incubated 5 min on ice with 0.5 mCi Na
125I
(IMS30, GE Healthcare UK Limited, Chalfont St.Giles, UK). The
specific activity was 5.7610
6 dpm/mg fibrinogen. The radio-
iodonated fibrinogen was diluted with unlabelled fibrinogen to
achieve appropriate total fibrinogen concentration.
N-terminal sequencing was done by running protein samples on
a 10% Novex Bis-Tris NuPAGE precast gel using MES buffer in
a Novex6Cell II Mini-Cell gel apparatus. The protein bands were
electroblotted onto a Novex 0.2 mm PVDF membrane (Invitrogen)
using a Novex Blot module. The membrane was stained with
Coomassie Brilliant Blue and target bands were excised. These
were washed with 10% methanol and sequenced on a 494A
Procise protein sequencer (Applied Biosystems, Warrington, UK)
for 10 cycles using standard sequencing cycles [29].
Incubation of prothrombin with activated trMASP2,
trMASP1 or factor Xa
Prothrombin 3.3 mg (Haematologic Technologies Inc (HTI), Essex
Junction, VT) was incubated with 30 ng factor Xa (HTI) or
truncated rMASP2 (CCP1-CCP2-SP) [9] or trMASP1 (CCP1-
CCP2-SP) [9] in 20 mM Hepes, 140 mM NaCl, 5 mM CaCl2,
0.05% Tween20 pH 7.4 (activation buffer) at 37uC in a total
reaction volume of 30 ml. The samples were diluted 1:1 in
reducing sample buffer and analyzed on SDS-PAGE.
Incubation of prothrombin with other proteases
Prothrombin (2 mg) in a total volume of 30 ml was incubated as
above alone or in the presence of 60 ng activated C1s, a mixture of
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mixtures were purified as described in [30].
Effect of factor Xa and MASP2 on VPR-AMC
substrate turnover by prothrombin
To Microfluor
H white 96-well microtiter plate wells (Thermo
Labsystems, Franklin, MA) were added 10 mg of prothrombin and
25 or 100 ng factor Xa or trMASP2, respectively. The thrombin
substrate, Val-Pro-Arg-aminomethyl coumarin (VPR-AMC) (Ba-
chem, Bubendorf, Switzerland) was added to a final concentration
of 100 mM. The final volume/ well was 100 ml and reagents were
all diluted in activation buffer. The samples were incubated for
1 hour at room temperature. The amount of cleaved substrate was
continuously monitored and quantified in a microtiter plate reader
(Fluoroscan, Thermo Life Sciences, Basingstoke, UK)
Fibrinogen activation by rMBL and rMASP2
complexes
Rat rMBL-A [12] and full-length rMASP2K [13] were both
expressed in the Chinese hamster ovary cell-line DXB11 using the
pED vector [31]. The MASP2K has the arginine at the zymogen
activation cleavage site replaced by a lysine residue. This yields an
active form of MASP2 that is secreted as zymogen but is more stable
than wild-type MASP2, since it only autoactivates in complex with
MBL upon binding to a suitable surface [13]. The Arg to Lys
mutation of MASP2K is not in the serine protease domain but in the
linker region immediately preceeding it. The activated protease
domains of wild-type MASP2 and MASP2K are thus identical. As
expected, the MASP2K and wild-type MASP2 constructs cleave
protein substrates (C2 or C4) with similar Km and kcat [9,13,32].
A 96-well Maxisorb microtiter plate (Nunc, Kamstrup, Den-
mark) was coated with 10 mg/ well mannan (Sigma-Aldrich,
St.Louis, MO) in 0.1 M NaHCO3, pH 9.6 (coating buffer)
overnight at 4uC. The volume added to each well was 100 ml
unless otherwise stated. Residual binding sites were blocked with
200 ml of 1 mg/ml BSA in PBS/EDTA for 1h at room
temperature. The wells were washed three times with activation
buffer. Rat rMBL-A (0.12 mg) was preincubated in 100 ml
activation buffer with or without 0.12 mg rat rMASP2K for
1 hour at 4uC. At the end of the incubation, sodium EDTA,
pH 7.4 (final concentration 10 mM) was added to some samples to
provide negative controls. Preincubated samples were then
transferred to the mannan-coated wells, and left overnight at
4uC to allow the MBL/MASP2K complexes to bind to the
mannan. The wells were then washed with activation buffer.
Prothrombin (10 mg) and either fibrinogen (30 mg) or VPR-AMC
(final concentration 100 mM) in 100 ml activation buffer was
added to each well. The wells were incubated for at 37uC or room
temperature, then analyzed either by SDS-PAGE to observe
fibrinogen cleavage and polymerization, or in a fluorimeter to
measure VPR-AMC turnover. Controls without prothrombin
were also included. Fibrin clot formation was visualized by
incubating a 2-fold dilution series of preincubated MBL/
MASP2K complexes (starting at 0.2 mg) in 100 ml activation
buffer in the mannan-coated microtiter plates as described above.
Following the incubation the wells were washed three times with
200 ml activation buffer and incubated with 100 ml activation
buffer with 10 mg prothrombin and 100 mg fibrinogen at 37uC.
The light scatter at OD405 was used as a measure of fibrin
polymerization as described in [33]. The % of maximum
absorption was calculated by dividing the reading by that from
wells incubated with 100 mg fibrinogen and 0.1 unit of human
thrombin (Sigma-Aldrich).
Fibrinogen deposition on mannan/ fibrinogen
coated wells
Microtiter wells were coated with 100 mlo f5mg/ml fibrinogen
plus 5 mg/ml mannan in coating buffer overnight at 4uC. The
wells were then blocked and washed as described above.
Preformed rMBL/rMASP2K complexes (0.2 mg) were bound to
the wells in 100 ml activation buffer and incubated overnight at
4uC. Controls with 10 mM EDTA, or with no MASP2K, were
included. Wells were washed as before with activation buffer and
100 ml activation buffer with 10 mg prothrombin and 30 mg
125I-
fibrinogen (30.000 cpm) added and incubated 37uC. An additional
control without prothrombin was included. After the incubation
wells were washed and the bound
125I-fibrin was quantified by
measuring the whole well in a mini-assay type 6–20 gamma
counter (Mini-instruments Ltd, Burnham-on-Crouch, UK).
Fibrinogen deposition on Staphylococcus aureus
derivatized beads
Dynabeads
H M-270 Amine (Invitrogen Ltd) derivatized with
formalin-fixed whole S. aureus were prepared the following way.
The S. aureus Wood strain (National Institutes of Health, Bethesda,
MD) were grown and formalin fixed as described in [15] and
beads and bacteria (approximately 1610
9 and 1610
10, respec-
tively), were washed into 0.1 M sodium citrate, 140 mM NaCl,
pH 9.5 in a total volume of 250 ml. The beads and the bacteria
were mixed and sodium cyanoborohydride (Sigma-Aldrich) was
added to a final concentration of 50 mM and incubated with
stirring for 2 hours at room temperature. Residual active groups
on the beads were blocked by 0.1 M ethanolamine pH 8.4 for
1 hour. After blocking the beads were washed and stored in
activation buffer. MBL/MASP2K complexes were prepared as
described above. S. aureus derivatized beads (2.5610
7) were mixed
and incubated overnight at 4uC with 0.72 mg preformed MBL/
MASP2K complexes in a total volume of 0.3 ml on a slow rotary
stirrer. The beads were washed three times with 1 ml of activation
buffer. The beads were resuspended in 0.5 ml activation buffer
containing 50 mg prothrombin and
125I-fibrinogen (15 mg, 300000
cpm) and incubated at 37uC on a slow rotary stirrer. Controls with
1 mM Pefabloc SC (Pentapharm, Basle, Switzerland), 1 mg/ml
human C1 inhibitor prepared as described in [34,35] or 1 mM
iodoacetamide (Sigma-Aldrich) were also prepared. After in-
cubation the beads were washed and transferred to a new tube.
The radioactivity associated with the beads was measured in the
counter. The beads were resuspended and incubated in 6M urea
(500 ml) for 30 min at room temperature with stirring. The
radioactivity associated with the beads was measured as before.
Specificity of prothrombin activation by MASP2
The potential cleavage and activation of other protease proen-
zymes namely plasminogen and prekallikrein by trMASP2 was
tested as follows: Plasminogen (AB KABI, Stockholm, Sweden)
and prekallikrein (Enzyme Research Laboratories Ltd.) (2 mg)
were incubated with 20 ng trMASP2 or trMASP1 in 20 mlo f
activation buffer and for 1 hour or 16 hours at 37uC and analyzed
on SDS-PAGE to determine whether the proenzymes had been
cleaved. Formation of the active enzymes was assessed by
incubating plasminogen or prekallikrein (1 mg) with 20 ng
trMASP2 in a total volume of 200 ml activation buffer at room
temperature with 100 mM Val-Leu-Lys-AMC or Phe-Pro-Arg-
AMC, respectively, and the substrate turnover was measured for
2 hours. The two substrates are relatively specific for plasmin and
kallikrein, respectively but are not cleaved by MASP2 [10].
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